P2RY10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL162609	0.56	15/20
SCHEMBL274798	0.72	12/20
SCHEMBL274812	0.72	12/20
SCHEMBL274999	0.76	11/20
SCHEMBL23963	0.75	11/20
Phosphatidyl Serine (SCHEMBL24649)	0.75	11/20
SCHEMBL25552	0.75	11/20
SCHEMBL237694	0.75	11/20
SCHEMBL314019	0.75	11/20
SCHEMBL416554	0.75	11/20
SCHEMBL417532	0.73	11/20
SCHEMBL360370	0.67	11/20
SCHEMBL752723	0.60	11/20
SCHEMBL479757	0.58	11/20
SCHEMBL750205	0.50	11/20
SCHEMBL275621	0.71	10/20
SCHEMBL609831	0.65	10/20
SCHEMBL236702	0.56	10/20
SCHEMBL22762	0.55	10/20
SCHEMBL275075	0.51	10/20

Clinical trials — most relevant to P2RY10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism	PHASE4	COMPLETED
Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects	PHASE4	COMPLETED
Reversing Ticagrelor's Effects With Fresh Platelets	PHASE4	COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy	PHASE2	RECRUITING
Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention	PHASE2	UNKNOWN
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese	PHASE1	COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	EARLY_PHASE1	COMPLETED
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients	nan	RECRUITING
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
Cytokines in Papillon-Lefèvre Syndrome	nan	COMPLETED
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
BIOmarkers and PLAtelet Function Assessment in Myocardial Ischemia and Non Obstructive Coronary Arteries Study	nan	RECRUITING
Study of AggreGuide A-100 (ADP) Assay	nan	COMPLETED
Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy	nan	UNKNOWN
In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid	nan	COMPLETED
PDE5i Use in Renal Transplant Recipients	nan	WITHDRAWN
Suppressive Functions of Regulatory T Cells in Migraine	nan	NOT_YET_RECRUITING
Platelet Function in Resuscitated Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY10 binder may also engage these)

Protein	Name	Similarity
Q3U507	—	1.000	Q3U507 →
Q8BFU7	—	1.000	Q8BFU7 →
D4A7K7	—	0.999	D4A7K7 →
Q3U6B2	—	0.996	Q3U6B2 →
Q61038	—	0.996	Q61038 →
Q924T8	—	0.995	Q924T8 →
GPR183	G-protein coupled receptor 183	0.994	landscape →
GPR174	Probable G-protein coupled receptor 174	0.993	landscape →
Q9GK76	—	0.993	Q9GK76 →
A5PLE7	—	0.992	A5PLE7 →
Q9TTY5	—	0.991	Q9TTY5 →
Q2NNR5	—	0.991	Q2NNR5 →
Q99JA4	—	0.990	Q99JA4 →
GPR65	G-protein coupled receptor 65	0.990	landscape →
Q9XSD4	—	0.990	Q9XSD4 →
Q4G072	—	0.989	Q4G072 →
GPR55	G-protein coupled receptor 55	0.988	landscape →
P59902	—	0.987	P59902 →
LPAR4	Lysophosphatidic acid receptor 4	0.987	landscape →
Q8BG55	—	0.986	Q8BG55 →
Q95N02	—	0.986	Q95N02 →
Q80Z39	—	0.986	Q80Z39 →
B0UXR0	—	0.986	B0UXR0 →
D4A4Q2	—	0.985	D4A4Q2 →
CYSLTR2	Cysteinyl leukotriene receptor 2	0.985	landscape →
Q8C131	—	0.985	Q8C131 →
P21556	—	0.984	P21556 →
B5X337	—	0.984	B5X337 →
Q9ESG6	—	0.984	Q9ESG6 →
CYSLTR1	Cysteinyl leukotriene receptor 1	0.984	landscape →